XML 92 R73.htm IDEA: XBRL DOCUMENT v3.4.0.3
ACQUISITIONS - Pro Forma Impact of Business Combinations (Details) - USD ($)
$ / shares in Units, $ in Millions
12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Pro forma of consolidated results of operations      
Revenues $ 10,709.6 $ 10,247.6 $ 7,929.9
Net loss attributable to Valeant Pharmaceuticals International, Inc. $ (619.1) $ (374.7) $ (801.9)
Loss per share attributable to Valeant Pharmaceuticals International, Inc.:      
Basic (in usd per share) $ (1.80) $ (1.09) $ (2.43)
Diluted (in usd per share) $ (1.80) $ (1.09) $ (2.43)